Clinical Trial Update: A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating the efficacy and safety of VESIcare (solifenacin) for urgency associated with overactive bladder; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED